17 Associations Endorsed Pharmaceutical Enterprise


June  29, 2015, Beijing: the 2015 China Forum on  Ethical Business Practices for Pharmaceutical Enterprises jointly organized by nine  pharmaceutical industry associations officially opened in Beijing today. Under the  theme of "Multi-Stakeholder Coordination and Implementation of Compliance",  this conference aims to promote the coordination between pharmaceutical and healthcare  sectors and regulatory authorities, enhance industry self-discipline and further  regulate the interactions between the healthcare and pharmaceutical sectors through  the promotion of Pharmaceutical  Enterprise Ethical Business Practice (hereinafter referred to as the " Ethical Business Practice") and strengthening  industry self-discipline. Deputy Director-General of the Bureau of Investigation  and Enforcement of the China Food and Drug Administration (CFDA) Mr. Xing Yong and  Director of Division of Exchange and Cooperation of the Departments of Small and  Medium-Sized Enterprises (SMEs) of the Ministry of Industry and Information Technology  (MIIT) Mr. Zhou Jian attended the forum and delivered speeches.


China played host to the APEC meetings of  2014. After the convening of the SME Business Ethics Forum under the theme of "Improving  the Business Ethics Environment for Medical Device and Pharmaceutical Sectors"  in early September of last year, the APEC SME Business Ethics Working Group released  the Nanjing Declaration on Improving Business Ethics in Medical Device and Biopharmaceutical  Sectors before 2020, which identified the following objectives for the medical device  and biomedicine industry of various APEC economies: between 2012 and 2015, the number  of medical devices and biomedicine associations compliant with the Ethical Business Practice will be doubled  and by 2020, efforts will be made to promote the adoption and implementation of  APEC principles by the entire industry. The Ethical  Business Practice originates from the APEC Codes of Business Ethics for Biopharmaceutical  Sector, known as the Mexico City Principles. With the inclusion of eight new pharmaceutical  industry associations at this conference, a total of 17 Chinese associations (with  the name list attached below) have joined in the promotion of Ethical Business Practice with extensive  representation in the industry.

Drug  R&D, manufacturing, distribution and consumption are highly relevant with the  life and health of patients. The complexity of product consumption and the diversity  and uncertainties of patient conditions require close interactions and communication  between healthcare and pharmaceutical sectors. In addition, the maximal protection  of patient interests may be achieved only by ensuring that such interactions comply  with ethics and are based on science. Achievement of this principle not only relies  upon self-discipline of pharmaceutical industry, but requires the support and coordination  of multiple regulatory authorities to guide the healthcare and pharmaceutical sectors  to reach a consensus on codes of ethics regarding interaction and cooperation between  the two sectors with patient interests at the heart, with a view to coordinating  the codes of conduct between pharmaceutical and healthcare sectors.

PricewaterhouseCoopers  and Underwriters Laboratories Inc. made presentations at the forum about experiences  on how to promote compliance to reduce corporate operational risks and how to create  corporate compliance systems. Officials from the Ministry of Commerce, the State  Administration of Traditional Chinese Medicine, the Chinese Pharmaceutical Association  (CPA), the Chinese Medical Doctor Association (CMDA) and the Chinese Medical Association  (CMA) attended this forum.

Advocating  entities of Codes of Ethics for Pharmaceutical Enterprises

China Pharmaceutical Industry Association  (CPIA)

China Chamber of Commerce for Import &  Export of Medicines & Health Products (CCCMHPIE)

China Pharmaceutical Industry Research and  Development Association (PhIRDA)

The R&D-based Pharmaceutical Association  Committee (RDPAC)

China Association of Traditional Chinese  Medicine (CATCM)

China Association of Pharmaceutical Commerce  (CAPC)

China Non-Prescription Medicines Association  (CNMA)

Pharmaceutical Enterprise Promotion Association  (CPEP)

China Association of Cultural Development  for Pharmaceutical Enterprises

All-China Federation of Industry and Commerce,  Medical Pharmaceutical Chamber

China Association for Medical Devices Industry  (CAMDI)

China Pharmaceutical Packaging Association  (CPPA)

China Medicine Education Association (CMEA)

China Pharmaceutical Enterprise Management  Association (CPEMA)

China Pharmaceutical Association of Plant  Engineering (CPAPE)

China Medicinal Biotechnology Association  (CMBA)

China Quality Association for Pharmaceuticals  (CQAP)

(Arranged in the order of Chinese pinyin)

Review  of Previous Rounds of the China Forum on Codes of Ethics for Pharmaceutical Enterprises:

On October 29, 2013, nine Chinese domestic  pharmaceutical associations and chambers of commerce jointly organized the "Launch  Ceremony of Pharmaceutical Enterprise  Ethical Business Practice" under the guidance of the  National Bureau of Corruption Prevention, the China Food and Drug Administration  (CFDA), and the State Administration of Traditional Chinese Medicine. At the launch  ceremony, the letter of appeal for the implementation of the Pharmaceutical  Enterprise Ethical Business Practice  for  Pharmaceutical Enterprises (hereinafter referred to as the "Codes of Ethics")  have been jointly signed by the China Pharmaceutical Industry Association (CPIA),  China Chamber of Commerce for Import & Export of Medicines & Health Products  (CCCMHPIE), China Pharmaceutical industry Research and Development Association (Sino-PhIRDA),  the R&D-based Pharmaceutical Association Committee (RDPAC), China Association  of Traditional Chinese Medicine (CATCM), China Association of Pharmaceutical Commerce  (CAPC), Pharmaceutical Enterprise Promotion Association (CPEP), and China Association  of Cultural Development for Pharmaceutical Enterprises. The letter of appeal calls  upon stakeholders of pharmaceutical sector to comply with the six principles of  dedication to health care and patients, honesty, independence, lawfulness, transparency  and accountability enshrined in the Pharmaceutical  Enterprise Ethical Business Practice, and comply with various clauses of the Pharmaceutical Enterprise Ethical  Business Practice. In addition, it also appeals that the government continue  enhancing reform, conduct administration in accordance with law, create incentives  and disincentives and clean up the market to regulate China's pharmaceutical market  and build a reliable and orderly healthcare market for the benefit of the people.

After the signing of implementation of the  letter of appeal for the Pharmaceutical  Enterprise Ethical Business Practice by nine pharmaceutical associations and  chambers of commerce in Beijing in 2013, nine pharmaceutical associations and chambers  of commerce held the 2014 China Forum on Ethical Business Practices for  Pharmaceutical Enterprises in Beijing on May 27, 2014 to further promote the implementation  of the Pharmaceutical Enterprise Ethical  Business Practice, strengthen industry credibility system development and proactively  implement industry self-discipline. The National Health and Family Planning Commission  (NHFPC), the China Food and Drug Administration (CFDA), the State Administration  of Traditional Chinese Medicine and the Ministry of Industry and Information Technology  (MIIT) attended the forum. At the forum, representatives of the nine associations  and six recommended enterprises of pharmaceutical industry and commerce shared their  experiences and reflections on the promotion, learning, understanding and implementation  of Pharmaceutical Enterprise Ethical  Business Practice. Meanwhile, in ensuring that patients have access to the most  appropriate diagnosis and treatment, patients, healthcare professionals, pharmaceutical  industry and relevant organizations all have unique roles and responsibilities.  Delegates of the International Federation of Pharmaceutical Manufactures Associations  (IFPMA) made presentations about the Consensual Framework Document on the Ethical  Cooperation among Patient Organizations, Health Care Professionals  and Pharmaceutical Industry instituted in Geneva in January 2014. Officials  of the Chinese Medical Association (CMA), the Chinese Pharmaceutical Association  (CPA), Chinese Medical Doctor Association (CMDA) and Chinese Hospital Association  attended the forum and expressed the agreement that patient interests and health  industry development can only be ensured by creating mutual trust and respect, coordinating Pharmaceutical Enterprise Ethical  Business Practice among stakeholders and adopting common objectives and principles.

Related articles: